Øystein Soug

Chief Executive Officer
Management
Targovax
Norway

Business Expert Clinical Research
Biography

Øystein Soug has 20 years’ experience from international banking, industry and biotech. The last six years before joining the Company he was CFO of Algeta ASA, where Mr Soug built up the functions of Finance, IR, Compliance, IT and HR. During his period in Algeta, the company started and completed a 900 patient Phase III trial, licenced its lead drug Xofigo with Bayer, built a US sales organization, launched Xofigo in the US, raised some USD 200 million in the capital markets and was sold for USD 2.9 billion to Bayer. Before Mr Soug’s current CEO role, he was CFO of Targovax from May 2015 to October 2016. Prior to biotech, Mr Soug held several positions with the Orkla Group and the European Bank for Reconstruction and Development (EBRD). He has a MSc in Economics and Finance from Universität St. Gallen in Switzerland. Mr Soug is a Norwegian citizen, and resides in Norway.

Research Intrest

international banking, industry and biotechnology, clinical trials